November 17, 2020

SESSION 1: WORLD-WIDE DADA2 COHORTS
TELL US SOMETHING NEW!

All times listed are in Eastern Standard Time (Washington D.C. time)

17

November

2020

7:00 a.m. - 7:40 a.m.

Sign into Virtual Conference
Check Internet | Check Audio & Video Connection


17

November

2020

7:40 a.m. - 8:10 a.m.

Welcome/Introductions/Agenda Overview
Chip Chambers, M.D. - Founder & President DADA2 Foundation
Dan Kastner, M.D., Ph.D. - Scientific Director NHGRI, National Institutes of Health, USA


17

November

2020

8:10 a.m. - 8:25 a.m.

India DADA2 Cohort - Inaugural DADA2 Conference Lecture
Aman Sharma, M.D. – Postgraduate Institute of Medical Education & Research, Chandigarh, India


17

November

2020

8:25 a.m. - 8:40 a.m.

Belgium DADA2 Cohort
Isabelle Meyts, M.D., Ph.D. – University Hospitals Gasthuisberg, Leuven, Belgium


17

November

2020

8:40 a.m. - 8:55 a.m.

Canada DADA2 Cohort
Kelly Brown, Ph.D. – BC Children’s Hospital Research Institute, Vancouver, BC, Canada


17

November

2020

8:55 a.m. - 9:10 a.m.

China DADA2 Cohort
Qing Zhou, M.D. – Zhejiang University, Hangzhou, China


17

November

2020

9:10 a.m. - 9:25 a.m.

England DADA2 Cohort
Samantha Cooray, M.D., Ph.D. – UCL Institute of Child Health, London, England


17

November

2020

9:25 a.m. - 9:40 a.m.

Finland DADA2 Cohort
Janna Saarela, M.D., Ph.D. - Institute for Molecular Medicine, Helsinki, Finland


17

November

2020

9:40 a.m. - 9:55 a.m.

France DADA2 Cohort
Alexandre Belot, M.D., Ph.D. - Hospices Civils de Lyon, Lyon, France
Sophie Georgin-Lavialle, M.D., Ph.D. - Pierre and Marie Curie University, Paris, France


17

November

2020

9:55 a.m. - 10:05 a.m.

BREAK


17

November

2020

10:05 a.m. - 10:20 a.m.

Germany DADA2 Cohort
Bodo Grimbacher, M.D. – Center for Chronic Immunodeficiency, Freiburg, Germany


17

November

2020

10:20 a.m. - 10:35 a.m. 

Israel DADA2 Cohort
Yackov Berkun, M.D. - Hadassah Hebrew University Medical Center, Jerusalem, Israel


17

November

2020

10:35 a.m. - 10:50 a.m.

Italy DADA2 Cohort
Marco Gattorno, M.D. - Giannina Gaslini Institute, Genoa, Italy


17

November

2020

10:50 a.m. - 11:05 a.m.

Japan DADA2 Cohort
Kazushi Izawa, M.D., Ph.D. – Kyoto University Hospital, Kyoto, Japan


17

November

2020

11:05 a.m. - 11:20 a.m.

Netherlands DADA2 Cohort
Joris Van Montfrans, M.D., Ph.D. – University Medical Center Utrecht, Utrecht, The Netherlands


17

November

2020

11:20 a.m. - 11:35 a.m.

NIH | USA DADA2 Cohort
Karyl Barron, M.D. – NIAID/NIH, Bethesda Maryland, USA


17

November

2020

11:35 a.m. - 11:50 a.m.

South America DADA2 Cohort
Gustavo Santo, M.D. – Hospitais da Universidade, Coimbra, Portugal


17

November

2020

11:50 a.m. - 12:05 p.m.

Spain DADA2 Cohort
Juan Ignacio Aróstegui, M.D. – Hospital Clinic-Biomedical Diagnostic Center, Barcelona, Spain


17

November

2020

12:05 p.m. - 12:20 p.m.

Turkey DADA2 Cohort
Seza Ozen, M.D. - Hacettepe University, Dept of Pediatrics, Ankara, Turkey


17

November

2020

12:20 p.m. - 12:30 p.m.

Q&A via Chat
Selected questions submitted through chat will be answered live by presenters, with remaining questions answered via written communication after the conference.


November 18, 2020

SESSION 2: NEW INSIGHTS IN DADA2
THINGS YOU NEED TO KNOW

All times listed are in Eastern Standard Time (Washington D.C. time)

18

November

2020

7:00 a.m. - 7:40 a.m.

Sign into Virtual Conference
Check Internet | Check Audio & Video Connection


18

November

2020

7:40 a.m. - 8:10 a.m.

Welcome/Introductions/Agenda Overview
Chip Chambers, M.D. - Founder & President DADA2 Foundation
Dan Kastner, M.D., Ph.D. - Scientific Director NHGRI, National Institutes of Health, USA


18

November

2020

8:10 - 8:30 a.m.

Neurological Phenotype of DADA2 – The Neurologists' Perspective
Timothy Bernard, M.D. University of Colorado School of Medicine, Denver, Colorado USA


18

November

2020

8:30 a.m. - 8:50 a.m.

Dermatological Phenotype of DADA2 – The Dermatologists' Perspective
Edward Cowen, M.D. – Dermatology Branch | NCI/NIH, Bethesda, Maryland USA


18

November

2020

8:50 a.m. - 9:10 a.m.

Non-Invasive Vascular Testing & Cardiac Phenotype of DADA2 – The Cardiologists' Perspective
Alessandra Brofferio, M.D. – NHLBI/NIH, Bethesda, Maryland USA


18

November

2020

9:10 a.m. - 9:30 a.m.

Immunodeficiency Phenotype of DADA2 – The Immunologists' Perspective
Troy Torgerson, M.D., Ph.D. – Allen Institute for Immunology, Seattle, Washington USA


18

November

2020

9:30 a.m. - 9:50 a.m.

Efficacy of TNF-Inhibitors in Treating DADA2
Amanda Ombrello, M.D. – NHGRI/NIH, Bethesda, Maryland USA


18

November

2020

9:50 a.m. - 10:00 a.m.

BREAK


18

November

2020

10:00 a.m. - 10:20 a.m.

Genotype & Functional Correlates of Disease Phenotype in DADA2
Pui Lee, M.D., Ph.D. – Harvard Medical School, Boston, Massachusetts USA


18

November

2020

10:20 a.m. - 10:40 a.m.

Analysis of DADA2 Pathogenesis Based on Single Cell RNA Sequencing of Monocytes
Alice Wu, M.D., Ph.D. – NHLBI/NIH, Bethesda, Maryland USA


18

November

2020

10:40 a.m. - 11:00 a.m.

How Not to Miss the Diagnosis of DADA2
Ivona Aksentijevich, M.D. – NHGRI/NIH, Bethesda, Maryland USA


18

November

2020

11:00 a.m. - 11:20 a.m.

The Diagnosis of DADA2 in 30 mins at the Point of Care – Is it Possible?
Carson Chen, Ph.D. - iXensor, Taipei City, Taiwan


18

November

2020

11:20 a.m. - 11:40 p.m.

Can the Prevalence of DADA2 be Estimated?
Anne O’Donnell Luria, M.D., Ph.D. – Broad Institute at MIT, Cambridge, Massachusetts USA
Samantha Baxter, MS, LGC – Broad Institute at MIT, Cambridge, Massachusetts USA


18

November

2020

11:40 a.m. - 12:30 p.m.

Q&A via Chat
Selected questions submitted through chat will be answered live by presenters, with remaining questions answered via written communication after the conference.


November 19, 2020

SESSION 3: FIRE SIDE CHATS
TOPICS THAT NEED A CONSENSUS

All times listed are in Eastern Standard Time (Washington D.C. time)

19

November

2020

7:00 a.m. - 7:40 a.m.

Sign into Virtual Conference
Check Internet | Check Audio & Video Connection


19

November

2020

7:40 a.m. - 8:00 a.m.

Welcome/Introductions/Agenda Overview
Chip Chambers, M.D. - Founder & President DADA2 Foundation
Dan Kastner, M.D., Ph.D. - Scientific Director NHGRI, National Institutes of Health USA


19

November

2020

8:00 a.m. - 8:20 a.m.

What to Do About the Asymptomatic DADA2 Patient?
Taryn Youngstein, M.D. - Imperial College Healthcare NHS Trust, London, England


19

November

2020

8:20 a.m. - 8:40 a.m.

Interpreting Variants of Unknown Significance in Patients with Sign/Symptoms of DADA2
Pui Lee, M.D., Ph.D. – Harvard Medical School, Boston, Massachusetts USA


19

November

2020

8:40 a.m. - 10:10 a.m.

What is the Function of ADA2? – Can We Design a Research Agenda to Answer that Question?
Sonia Sharma, Ph.D. – La Jolla Institute for Immunology, La Jolla, California USA
Ole Kristian Greiner-Tollersrud, Ph.D. – Institute of Medical Biology University of Tromsø, Norway
Michele Proeitti, M.D. Ph.D. – Center for Chronic Immunodeficiency, Freiburg, Germany
Peter Grayson, M.D. – NIAMS/NIH, Bethesda, Maryland USA
Kazushi Izawa, M.D., Ph.D. – Kyoto University Hospital, Kyoto, Japan
Dan Kastner, M.D., Ph.D. – Moderator | Scientific Director, NHGRI/NIH, Bethesda, Maryland USA


19

November

2020

10:10 a.m. - 11:00 a.m.

What is the Best Approach to Hematopoietic Stem Cell Transplant for DADA2?
Jennifer Kanakry, M.D. – NCI/NIH, Bethesda, Maryland USA
Isabelle Meyts, M.D., Ph.D. – University Hospitals Gasthuisberg, Leuven, Belgium
Mrinal Patnaik, MBBS – Moderator | Mayo Clinic, Rochester, Minnesota, USA


19

November

2020

11:00 a.m. - 12:10  p.m.

Can DADA2 be Cured by Gene Therapy & Gene Editing?
Despina Eleftheriou, MBBS, MRCPCH, Ph.D. - UCL Institute of Child Health, London, England
Alessandra Mortellaro, Ph.D. - San Raffaele Telethon Institute for Gene Therapy, Milan, Italy
Rachel Diamant, MSc Eng – EMENDO Biotherapeutics, New York, New York, USA
Harry Malech, M.D. – Moderator | NIAID/NIH, Bethesda, Maryland USA


19

November

2020

12:10 p.m. - 12:30 p.m.

Conclusion 3rd International Conference on the Deficiency of Adenosine Deaminase 2